AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19604194 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual in-line stabilisation
Number of subjects: 0
Study 19604194 — intervention group
Group type: COMPARATOR
Intervention: No manual in-line stabilisation
Number of subjects: 0
Study 16636217 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg subcutaneously once a week for 4 weeks
Number of subjects: 56
Study 16636217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 15257811 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 alpha-hydroxyprogesterone caproate (17-HPC) administered intramuscularly (341 mg every 3 days)
Number of subjects: 320
Study 15257811 — intervention group
Group type: COMPARATOR
Intervention: Intra-vaginal progesterone (90 mg daily)
Number of subjects: 320
Study 11169254 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-G*01011 allele
Number of subjects: 94
Study 11169254 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-G*01012 allele
Number of subjects: 94
Study 11169254 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-G*01013 allele
Number of subjects: 94
Study 11169254 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-G*0105N allele
Number of subjects: 94
Study 11169254 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-G*01041 allele
Number of subjects: 94
Study 9484876 — intervention group
Group type: EXPERIMENTAL
Intervention: grepafloxacin, 600 mg od
Number of subjects: 264
Study 9484876 — intervention group
Group type: COMPARATOR
Intervention: amoxycillin, 500 mg tds
Number of subjects: 264
Study 29097056 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy plus community-based bionic leg training program
Number of subjects: 0
Study 29097056 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy only
Number of subjects: 0
Study 29097056 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 0
Study 27566671 — intervention group
Group type: EXPERIMENTAL
Intervention: HFR-S
Number of subjects: 41
Study 27566671 — intervention group
Group type: EXPERIMENTAL
Intervention: HFR
Number of subjects: 41
Study 27566671 — intervention group
Group type: COMPARATOR
Intervention: ol-HDF
Number of subjects: 41
Study 25953472 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrysof SA60AT (interrupted optic edge) IOL
Number of subjects: 50
Study 25953472 — intervention group
Group type: COMPARATOR
Intervention: Tecnis ZCB00 (continuous optic edge) IOL
Number of subjects: 50
Study 25953472 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IOLs
Number of subjects: 50
Study 23257680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone dipropionate (nBDP) 800 µg, administered twice daily for 4 weeks
Number of subjects: 40
Study 23257680 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized beclomethasone dipropionate (nBDP)
Number of subjects: 40
Study 23257680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19650848 — intervention group
Group type: EXPERIMENTAL
Intervention: MHRV (mechanical heat recovery ventilation)
Number of subjects: 120
Study 19650848 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 120
Study 17684134 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination botanical supplement (Curcuma longa, Cynara scolymus, Rosmarinus officinalis, Schisandra chinensis, Silybum marinum, and Taraxacum officinalis; n = 15)
Number of subjects: 40
Study 17684134 — intervention group
Group type: COMPARATOR
Intervention: Dietary changes (3 servings/d crucifers or dark leafy greens, 30 g/d fiber, 1‐2 liters/d water, and limiting caffeine and alcohol consumption to 1 serving each/wk; n = 10)
Number of subjects: 40
Study 17684134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 15)
Number of subjects: 40
Study 14605834 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidectomy
Number of subjects: 100
Study 14605834 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemorrhoidectomy
Number of subjects: 100
Study 11800416 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10-20 mg per day)
Number of subjects: 253
Study 11800416 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 253
Study 11038811 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposuspension
Number of subjects: 95
Study 11038811 — intervention group
Group type: COMPARATOR
Intervention: Kelly operation
Number of subjects: 95
Study 7977602 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma fibrinogen levels
Number of subjects: 198
Study 7977602 — intervention group
Group type: EXPERIMENTAL
Intervention: History of glaucoma
Number of subjects: 198
Study 7977602 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fibrinogen level (in women)
Number of subjects: 198
Study 7977602 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen use (in women)
Number of subjects: 198
Study 2659634 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusin restorations
Number of subjects: 447
Study 2659634 — intervention group
Group type: COMPARATOR
Intervention: Amalgam restorations
Number of subjects: 447
Study 791381 — intervention group
Group type: EXPERIMENTAL
Intervention: Jacobson-Wolpe autogenic-relaxation training
Number of subjects: 18
Study 791381 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG relaxation training
Number of subjects: 18
Study 791381 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG relaxation training combined with Jacobson-Wolpe autogenic instructions
Number of subjects: 18
Study 791381 — intervention group
Group type: COMPARATOR
Intervention: Verbal relaxation instructions
Number of subjects: 18
Study 30375309 — intervention group
Group type: EXPERIMENTAL
Intervention: ToyBox-intervention
Number of subjects: 5212
Study 27707640 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water
Number of subjects: 96
Study 27707640 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn Cool Spray®
Number of subjects: 96
Study 27707640 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnshield®
Number of subjects: 96
Study 26332930 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral family weight management intervention
Number of subjects: 93
Study 26332930 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 93
Study 24490063 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 61
Study 24490063 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemostasis (CH)
Number of subjects: 61
Study 21575819 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher scores on hostility
Number of subjects: 1771
Study 21575819 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher scores on depressive symptoms
Number of subjects: 1771
Study 21575819 — intervention group
Group type: EXPERIMENTAL
Intervention: Being bully-victims
Number of subjects: 1771
Study 19649375 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions for weight gain management
Number of subjects: 0
Study 17374659 — intervention group
Group type: EXPERIMENTAL
Intervention: High linoleic acid (LA) diet
Number of subjects: 22
Study 17374659 — intervention group
Group type: COMPARATOR
Intervention: Low linoleic acid (LA) diet
Number of subjects: 22
Study 15125626 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 136
Study 15125626 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical management
Number of subjects: 136
Study 15125626 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management (successful spontaneous loss)
Number of subjects: 136
Study 15125626 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed according to own choice (Expectant)
Number of subjects: 136
Study 15125626 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed according to own choice (Surgical)
Number of subjects: 136
Study 11519628 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Workplace
Number of subjects: 40
Study 11519628 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 40
Study 9282426 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (Arimidex‐Zeneca)
Number of subjects: 0
Study 9282426 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (Femara‐Novartis)
Number of subjects: 0
Study 9282426 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate
Number of subjects: 0
Study 7946232 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-door policy combined with a structured activity programme (experimental group)
Number of subjects: 50
Study 7946232 — intervention group
Group type: COMPARATOR
Intervention: Control group (not permitted to leave the ward, no participation in activities)
Number of subjects: 50
Study 3284421 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg clonidine
Number of subjects: 80
Study 3284421 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg adrenaline
Number of subjects: 80
Study 3284421 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg adrenaline
Number of subjects: 80
Study 3284421 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasoconstrictors (0.15 mg clonidine or 0.4 mg adrenaline)
Number of subjects: 80
Study 3284421 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 80
Study 31560783 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0
Study 27541270 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ibuprofen (IIBU)
Number of subjects: 850
Study 27541270 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed ibuprofen (DIBU)
Number of subjects: 850
Study 27541270 — intervention group
Group type: COMPARATOR
Intervention: No ibuprofen (NIBU)
Number of subjects: 850
Study 27541270 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (IPARA)
Number of subjects: 850
Study 27541270 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed paracetamol (DPARA)
Number of subjects: 850
Study 27541270 — intervention group
Group type: COMPARATOR
Intervention: No paracetamol (NPARA)
Number of subjects: 850
Study 25596571 — intervention group
Group type: EXPERIMENTAL
Intervention: Brucella infection (patient group)
Number of subjects: 24
Study 25596571 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 healthy individuals)
Number of subjects: 24
Study 23275387 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone daily for 2 years (P-group)
Number of subjects: 225
Study 23275387 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone (NoP-group)
Number of subjects: 225
Study 23275387 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg prednisolone daily (P-group)
Number of subjects: 225
Study 22147238 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available dentifrice with added mineral oil (Nujol®) for group 2 (G2)
Number of subjects: 30
Study 22147238 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially available dentifrice with added vegetable oil (Alpha Care®) for group 3 (G3)
Number of subjects: 30
Study 22147238 — intervention group
Group type: COMPARATOR
Intervention: Commercially available dentifrice (control group 1 - G1)
Number of subjects: 30
Study 19028705 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nicotinamide (1500 or 500 mg daily for 1 week)
Number of subjects: 0
Study 19028705 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered for 1 week)
Number of subjects: 0
Study 17258215 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy with instillation of human endometrioma material, no lavage
Number of subjects: 24
Study 17258215 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopy with instillation of human endometrioma material, followed by clearance of all visible endometrioma fluid by saline lavage and suction
Number of subjects: 24
Study 17258215 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy alone
Number of subjects: 24
Study 15168386 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 34
Study 15168386 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 34
Study 11470690 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate nuclear opacities
Number of subjects: 4477
Study 11470690 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate cortical opacities
Number of subjects: 4477
Study 9923984 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic preparation 'Tinnitus' (D60 potency)
Number of subjects: 28
Study 9923984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7828257 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.1 mg.ml‐1)
Number of subjects: 24
Study 7828257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3056209 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular diclofenac
Number of subjects: 114
Study 3056209 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular papaveretum
Number of subjects: 114
Study 3056209 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 114
Study 31406237 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine treatment
Number of subjects: 114
Study 29975623 — intervention group
Group type: EXPERIMENTAL
Intervention: IFRT plus six cycles of cyclophosphamide, vincristine, and prednisolone (CVP) or R-CVP (with rituximab)
Number of subjects: 150
Study 29975623 — intervention group
Group type: COMPARATOR
Intervention: IFRT alone
Number of subjects: 150
Study 29975623 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CVP (with rituximab)
Number of subjects: 150
Study 26606887 — intervention group
Group type: EXPERIMENTAL
Intervention: Low SSB (≤1 SSB serv/day)
Number of subjects: 47
Study 26606887 — intervention group
Group type: COMPARATOR
Intervention: High SSB (≥2 serv/day)
Number of subjects: 47
Study 26606887 — intervention group
Group type: COMPARATOR
Intervention: Medium SSB (>1 - <2 serv/day)
Number of subjects: 47
Study 24242902 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 525797 (DI17E6) 35, 100, 250, 500, 1000, or 1500 mg
Number of subjects: 55
Study 24242902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 24242902 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD 525797 (DI17E6)
Number of subjects: 55
Study 22042368 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant aromatase inhibitor therapy
Number of subjects: 415
Study 21135341 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-method protection use
Number of subjects: 701
Study 21135341 — intervention group
Group type: COMPARATOR
Intervention: Dual-method protection users
Number of subjects: 701
Study 17693918 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus strain GG (Culturelle, ConAgra Foods, Omaha, NE)
Number of subjects: 61
Study 17693918 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule of insulin
Number of subjects: 61
Study 15834298 — intervention group
Group type: EXPERIMENTAL
Intervention: COER-verapamil
Number of subjects: 16602
Study 15834298 — intervention group
Group type: COMPARATOR
Intervention: Atenolol or hydrochlorothiazide (investigator's choice)
Number of subjects: 16602
Study 12042429 — intervention group
Group type: EXPERIMENTAL
Intervention: Barley bread containing lactic acid
Number of subjects: 10
Study 12042429 — intervention group
Group type: COMPARATOR
Intervention: Reference barley bread (without lactic acid)
Number of subjects: 10
Study 10223935 — intervention group
Group type: EXPERIMENTAL
Intervention: Penciclovir (PCV) 5 mg/kg every 12 hours (q12h)
Number of subjects: 342
Study 10223935 — intervention group
Group type: EXPERIMENTAL
Intervention: Penciclovir (PCV) 5 mg/kg every 8 hours (q8h)
Number of subjects: 342
Study 10223935 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir (ACV) 5 mg/kg every 8 hours (q8h)
Number of subjects: 342
Study 10223935 — intervention group
Group type: COMPARATOR
Intervention: Penciclovir (PCV) q12h vs Acyclovir (ACV) q8h
Number of subjects: 342
Study 10223935 — intervention group
Group type: COMPARATOR
Intervention: Penciclovir (PCV) q8h vs Acyclovir (ACV) q8h
Number of subjects: 342
Study 10223935 — intervention group
Group type: COMPARATOR
Intervention: Penciclovir (PCV) q12h or q8h vs Acyclovir (ACV) q8h
Number of subjects: 342
Study 10150324 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (1 g + 0.5 g)
Number of subjects: 58
Study 10150324 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (0.5 g)
Number of subjects: 58
Study 10150324 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (1 g)
Number of subjects: 58
Study 2142172 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% triethanolamine application
Number of subjects: 20
Study 2142172 — intervention group
Group type: COMPARATOR
Intervention: Aqueous cream
Number of subjects: 20
Study 2142172 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (triethanolamine and aqueous cream)
Number of subjects: 20
Study 368364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalosporin therapy
Number of subjects: 57
Study 368364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 31113338 — intervention group
Group type: COMPARATOR
Intervention: Substantial Clinical Improvement (SCI) at d0 (30% improvement in NIHSS)
Number of subjects: 423
Study 31113338 — intervention group
Group type: COMPARATOR
Intervention: Substantial Clinical Improvement (SCI) at d1 (40% improvement in NIHSS)
Number of subjects: 423
Study 31113338 — intervention group
Group type: COMPARATOR
Intervention: Substantial Clinical Improvement (SCI) at d7 (70% improvement in NIHSS)
Number of subjects: 423
Study 31113338 — intervention group
Group type: COMPARATOR
Intervention: Successful reperfusion
Number of subjects: 423
Study 31113338 — intervention group
Group type: COMPARATOR
Intervention: Shorter time to treatment
Number of subjects: 423
Study 29117152 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed mobile data gathering scheme using Metropolis-Hastings algorithm with delayed acceptance and Kronecker compressive sensing (KCS)
Number of subjects: 0
Study 29117152 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed mobile data gathering scheme
Number of subjects: 0
Study 25721698 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg vitamin D3 daily
Number of subjects: 305
Study 25721698 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg vitamin D3 daily
Number of subjects: 305
Study 25721698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 23874597 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced community‐based voluntary counseling and testing
Number of subjects: 50000
Study 23874597 — intervention group
Group type: COMPARATOR
Intervention: Control communities (not explicitly defined in the abstract)
Number of subjects: 50000
Study 20807322 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg on-demand vardenafil ODT
Number of subjects: 701
Study 20807322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 701
Study 19491798 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinupret in age-adjusted doses
Number of subjects: 40
Study 19491798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Sinupret)
Number of subjects: 40
Study 17261211 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group 1)
Number of subjects: 90
Study 17261211 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 150 microg kg‐1 intravenously at dural closure (Group 2)
Number of subjects: 90
Study 17261211 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of Ondansetron 150 microg kg‐1 intravenously, second dose after 6 h (Group 3)
Number of subjects: 90
Study 14736597 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol at home
Number of subjects: 120
Study 14736597 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol at hospital
Number of subjects: 120
Study 11699470 — intervention group
Group type: EXPERIMENTAL
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 16
Study 11699470 — intervention group
Group type: COMPARATOR
Intervention: Guided tissue regeneration-based procedure (GTRC)
Number of subjects: 16
Study 9322619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Papanicolaou smear
Number of subjects: 210
Study 9322619 — intervention group
Group type: COMPARATOR
Intervention: Gram stain of vaginal secretions
Number of subjects: 210
Study 7933819 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oral calcitriol (2 micrograms thrice weekly, increased to 4 micrograms as tolerated)
Number of subjects: 19
Study 7933819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol (2 micrograms thrice weekly, increased to 4 micrograms as tolerated)
Number of subjects: 19
Study 7933819 — intervention group
Group type: COMPARATOR
Intervention: Both pulse oral and intravenous calcitriol
Number of subjects: 19
Study 2952091 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cigarette (nicotine content: 1.1 mg)
Number of subjects: 15
Study 2952091 — intervention group
Group type: EXPERIMENTAL
Intervention: Light cigarette (nicotine content: 0.6 mg)
Number of subjects: 15
Study 2952091 — intervention group
Group type: COMPARATOR
Intervention: Comparison of regular vs light cigarette
Number of subjects: 15
Study 29807477 — intervention group
Group type: EXPERIMENTAL
Intervention: belimumab 200 mg SC
Number of subjects: 662
Study 29807477 — intervention group
Group type: COMPARATOR
Intervention: placebo to belimumab
Number of subjects: 662
Study 27871284 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilisation (n=54, active group)
Number of subjects: 109
Study 27871284 — intervention group
Group type: COMPARATOR
Intervention: Continued plaster cast fixation for another 3 weeks (n=55, control group)
Number of subjects: 109
Study 24449708 — intervention group
Group type: EXPERIMENTAL
Intervention: Melodic Intonation Therapy (MIT)
Number of subjects: 27
Study 24449708 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (waiting-list control)
Number of subjects: 27
Study 24449708 — intervention group
Group type: COMPARATOR
Intervention: Delayed MIT (received by control group after initial intervention)
Number of subjects: 27
Study 16402746 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit task (tune stem completion)
Number of subjects: 0
Study 16402746 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit task (cued recall)
Number of subjects: 0